Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

SOSalman OtoukeshCity of HopePKPaul KollerCity of HopeABAmanda BlackmonCity Of Hope National Medical Center

Discussion

Loading...

Member takes

Overview

Retrospective analysis reports worse progression-free survival in patients with TP53 alterations and high disease risk index.

Key Points

  • The aim is to evaluate HCT outcomes and identify prognostic variables in patients with TP53-altered acute leukemia or MDS.
  • Conducted a retrospective analysis of 158 allogeneic HCT patients with TP53 alterations.
  • Collected data on demographics, cytogenetics, MRD via flow cytometry or PCR, and conditioning regimens.
  • Analyzed outcomes including overall survival, progression-free survival, and cumulative incidence of relapse and non-relapse mortality.
  • Median overall survival at two years was 45.6%, with progression-free survival at 36.6%.
  • Relapse rates at one and two years post-HCT were 34.1% and 37.8%, respectively.
  • MRD positivity and high disease risk index were significant predictors of worse progression-free survival.

Cite This Study

Otoukesh et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e536https://doi.org/10.1182/blood-2025-2516
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  2. 2Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT2025 · 1 citations
  3. 3Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations
  4. 4Clinical outcomes of <i>TP53</i> -mutated myeloid neoplasms after allogeneic hematopoietic cell transplantation: A Canadian multicenter propensity score–matched analysis.2026
  5. 5Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy2025